Corvus Pharmaceuticals (CRVS) said late Thursday that new interim data from a phase 1 clinical trial of soquelitinib to treat moderate to severe atopic dermatitis showed a "favorable" safety and efficacy profile.
The company found "earlier and deeper responses" in group 3, which received 200 milligrams twice a day, compared with groups 1 and 2, which received 100 mg twice daily and 200 mg once daily.
Corvus said that all three groups showed "significant responses" in the soquelitinib treatment groups, compared with placebo for clinically significant endpoints.
Atopic dermatitis is a skin condition characterized by dry, itchy, and inflamed skin.
Shares of the company were up 37% in recent premarket activity Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。